Abbvie: A Glimpse Of What The New Biopharma Will Look Like
This article was originally published in The Pink Sheet Daily
The proprietary pharmaceuticals business – slated to break off from Abbott on Jan. 1, 2013 – will generate sales of around $18 billion, have a cash balance of $7 billion and an annual R&D spend of around 14% of sales, about $2.52 billion in 2013.
You may also be interested in...
AbbVie Ventures is young, but the group was set up with specific goals: to invest specifically in tune with AbbVie's therapeutic focus areas and not to focus purely on return on investment.
The Illinois-based company will spin out its biopharma business by mid-2015, creating two public companies that will cater to vastly different markets. Yet, both companies are expected to boast strong balance sheets and be in position to make acquisitions.
The Russian government’s aggressive plan to modernize the country’s pharmaceutical industry is stimulating entrepreneurial activities, as well as a flurry of deal activity between local and foreign companies. Many uncertainties remain about the potential opportunities, however, as foreign companies try to sort out changing regulatory and business dynamics.